NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Forecast & News

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

GRIFOLS S A/S declared a semi-annual dividend on Thursday, October 31st. Investors of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a dividend yield of 1.3%. The ex-dividend date is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's Dividend History.

Shares of GRIFOLS S A/S split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were distributed to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

GRIFOLS S A/S (NASDAQ:GRFS) released its quarterly earnings results on Tuesday, October, 29th. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.03. The biotechnology company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.39 billion. GRIFOLS S A/S had a return on equity of 13.58% and a net margin of 11.12%. View GRIFOLS S A/S's Earnings History.

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for GRIFOLS S A/S.

6 Wall Street analysts have issued 12 month target prices for GRIFOLS S A/S's stock. Their forecasts range from $19.00 to $22.50. On average, they expect GRIFOLS S A/S's stock price to reach $20.75 in the next year. This suggests that the stock has a possible downside of 8.7%. View Analyst Price Targets for GRIFOLS S A/S.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GRIFOLS S A/S.

Media headlines about GRFS stock have been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for GRIFOLS S A/S.

GRIFOLS S A/S saw a increase in short interest in November. As of November 29th, there was short interest totalling 1,790,000 shares, an increase of 14.0% from the November 14th total of 1,570,000 shares. Based on an average daily trading volume, of 1,229,300 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.7% of the company's stock are short sold. View GRIFOLS S A/S's Current Options Chain.

Some companies that are related to GRIFOLS S A/S include Allergan (AGN), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG) and Teva Pharmaceutical Industries (TEVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Allergan (AGN), Teva Pharmaceutical Industries (TEVA), Nektar Therapeutics (NKTR), Southern Copper (SCCO), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG) and Alphabet (GOOG).

GRIFOLS S A/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Pictet Asset Management Ltd. (1.15%), First Trust Advisors LP (0.40%), Soros Fund Management LLC (0.30%), Millennium Management LLC (0.29%), Man Group plc (0.22%) and Beck Mack & Oliver LLC (0.17%).

GRFS stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Banco de Sabadell S.A, Soros Fund Management LLC, CWM LLC, Beck Mack & Oliver LLC, CIBC Asset Management Inc, Lenox Wealth Management Inc. and Crossmark Global Holdings Inc..

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Pictet Asset Management Ltd., Point72 Asset Management L.P., Barclays PLC, CIBC Private Wealth Group LLC, Squarepoint Ops LLC, Voloridge Investment Management LLC and State Street Corp.

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GRFS stock can currently be purchased for approximately $22.73.

GRIFOLS S A/S has a market capitalization of $15.63 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S.

The official website for GRIFOLS S A/S is http://www.grifols.com/.

GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected]